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Emerging Role of Insulin with Incretin Therapies for 
Management of Type 2 Diabetes
Rupa Ahluwalia · Jiten Vora
ABSTRACT 
Type 2 diabetes mellitus (T2DM) is a progressive 
disease warranting intensification of treatment, 
as beta-cell function declines over time. Current 
treatment algorithms recommend metformin 
as the first-line agent, while advocating the 
addition of either basal-bolus or premixed 
insulin as the final level of intervention. 
Incretin therapy, including incretin mimetics or 
enhancers, are the latest group of drugs available 
for treatment of T2DM. These agents act through 
the incretin axis, are currently recommended 
as add-on agents either as second- or third-line 
treatment, without concurrent use of insulin. 
Given the novel role of incretin therapy in 
terms of reducing postprandial hyperglycemia, 
and favorable effects on weight with reduced 
incidence of hypoglycemia, we explore 
alternative options for incretin therapy in T2DM 
management. Furthermore, as some evidence 
alludes to incretins potentially increasing beta-
cell mass and altering disease progression, we 
propose introducing these agents earlier in the 
treatment algorithm. In addition, we suggest the 
concurrent use of incretins with insulin, given 
the favorable effects especially in relation to 
weight gain. 
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INTRODUCTION
Type 2 diabetes mellitus (T2DM) is a 
progressive disease where hyperglycemia 
occurs when insulin secretion fails to keep pace 
with insulin resistance.1 Therefore, long-term 
disease management warrants intensification 
of treatment over time, especially in step 
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with declining beta-cell function.2 In general, 
T2DM management commences with lifestyle 
and dietary advice, with an oral antidiabetic 
drug (OAD) added if glycemic control 
remains or becomes suboptimal. Metformin 
is often recommended as the first-line 
pharmacotherapy given its well-established 
efficacy, as well as being weight-neutral and 
inexpensive.3 Metformin can be used in 
combination with other OADs or insulin, 
but the traditional OADs (sulfonylureas [SU] 
and thiazolidinediones [TZD]) and insulin 
are associated with weight gain, which can 
compromise patients’ ongoing attempts at 
weight reduction.4 At the point of introducing 
exogenous insulin, depending on national 
guidelines and individual preferences, OADs 
other than metformin are often discontinued. 
The ultimate level of intervention is to add 
mealtime bolus insulin to, typically, basal 
insulin plus metformin, or to substitute a 
premixed insulin regimen.
Over the last few years we have seen the 
advent of newer drugs in the form of incretin-
based therapies. These act primarily by 
increasing the physiological effects mediated 
via the hormone glucagon-like peptide-1 
(GLP-1), which is secreted along with glucose-
dependent insulinotropic polypeptide (GIP) by 
intestinal cells when food is ingested, probably 
via the neural and endocrine signals associated 
with feeding.5 GLP-1 and GIP have multiple 
actions that enhance beta-cell response in 
a glucose-dependent fashion. In T2DM, the 
incretin response is diminished.6 However, the 
insulinotropic action of GIP is diminished, 
while that of GLP-1 is preserved, although the 
secretion of GLP-1 appears to be diminished.7,8
Nevertheless, as the tissue sensitivity to GLP-1 
is preserved7,9 restoration of GLP-1 signal forms 
the basis of use of GLP-1 receptor agonists as a 
therapeutic option in T2DM.
Two strategies can restore the GLP-1 signal: 
inhibiting the enzyme dipeptidyl peptidase-4 
(DPP-4), which rapidly degrades GLP-1 
in vivo resulting in increased concentrations of 
endogenous GLP-1; or using DPP-4 resistant 
mimetics of GLP-1 (eg, GLP-1 receptor agonists 
[GLP-1RA]). Drugs acting through the former 
mechanism are called incretin enhancers, 
while those with the latter action are classed as 
incretin mimetics.
The various effects (both insulinotropic 
and extra-pancreatic) of GLP-1 are well 
documented. Most of these effects complement 
the role of incretin therapy in T2DM 
(Table 1).7,10-17 From a blood glucose-lowering 
point of view, the most appealing property is 
that GLP-1 glucose dependently increases insulin 
secretion and suppresses glucagon secretion. 
Therefore, these actions manifest only in the 
setting of hyperglycemia. Moreover, counter-
regulatory responses to hypoglycemia (including 
glucagon secretion) are fully preserved, even 
when pharmacological levels of GLP-1 are 
administered.18 In addition, GLP-1 induces 
satiety and has weight limiting effects,13,19,20 
along with potential beta-cell sparing actions.15,16 
DPP-4 inhibitors (incretin enhancers) are 
orally available drugs that are weight neutral 
Summary of pancreatic and extra-pancreatic effects of 
glucagon-like peptide-1 in humans.
Glucose-dependent stimulation of insulin secretion7
Glucose-dependent suppression of glucagon secretion7
Enhanced glucagon secretion during hypoglycemia10,11
Reduced gastrointestinal motility and pancreatic exocrine 
function12
Increased satiety13
Improvement of beta-cell function14
 Increased beta-cell mass with inhibition of beta-cell 
apoptosis15-17
Table 1. Potential benefit of incretin therapy in the 
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with low propensity to cause hypoglycemia.5,21,22
Several DPP-4 inhibitors have been developed 
(e.g. vildagliptin, sitagliptin, saxagliptin). 
Currently, two GLP-1RA (incretin mimetics) 
are clinically available (exenatide, which is 
administered twice daily [b.i.d.] and liraglutide, 
administered once daily [o.d.]). Both are given 
subcutaneously. GLP-1RA reduce hyperglycemia 
in T2DM either when given as monotherapy 
or when added to various OAD regimens, and 
incretin mimetics often achieve weight loss.5 
Like DPP-4 inhibitors, GLP-1RA carry a low risk 
of hypoglycemia. Gastrointestinal adverse effects 
are transient, with nausea generally subsiding by 
8 weeks after initiation of exenatide treatment 
and by 4 weeks after initiation of liraglutide 
treatment.23
Even though incretin enhancers and 
mimetics act through the same therapeutic axis, 
their overall drug profile varies (Table 2). Hence, 
these differences offer a unique role for each of 
the drug groups in the treatment algorithm for 
T2DM. 
SAFETY AND ADVERSE EVENTS 
WITH INCRETIN BASED THERAPY
The most common side effect with GLP-1RA 
is nausea and, occasionally, vomiting. The 
frequency of gastrointestinal adverse events 
is less pronounced with DPP-4 inhibitors. 
Generally symptoms diminish over time. 
Some patients have reported diarrhea with 
GLP-1RA. Post-marketing cases of acute 
pancreatitis in patients treated with exenatide 
and acute pancreatitis in patients treated with 
liraglutide in clinical trials have led to amended 
label precautions for these agents. Similar 
case reports with sitagliptin (88 cases reported 
to the Food and Drug Administration [FDA] 
between October 2006 and February 2009) have 
been reported. However, patients with T2DM 
have a three-fold increased risk of pancreatitis 
compared with individuals who do not have 
diabetes.24 In summary, the data so far does not 
establish causality in terms of the use of incretin-
based therapy, and a possible increase incidence 
in pancreatitis. However, a precautionary note 
is now included in all the drug labels and also 
warrants appropriate patient education.
Thyroid neoplasia preclinical rodent studies 
with liraglutide have shown an increase in 
C-cell thyroid cancer, which so far has not been 
demonstrated in monkeys or humans.25 Based 
on the preclinical studies in rodents, the FDA 
has requested a boxed warning for liraglutide, 
which includes contraindications for use in 
“…patients with a personal or family history 
of medullary thyroid carcinoma (MTC) or in 
patients with Multiple Endocrine Neoplasia 
syndrome type 2 (MEN 2).”25 Recent findings 
from a large screening study in 5000 subjects 
treated with liraglutide did not support an 
effect of GLP-1 receptor activation on serum 
calcitonin levels in humans, as reported in 
rodent studies.26 However, ongoing studies are 
evaluating the long-term safety of incretin-
based therapy.
Other adverse events include hypoglycemia, 
particularly when GLP-1RA are used in 
conjunction with other OAD, especially 
secretagogs. Injection site-related adverse events, 
such as itching and skin rashes, have also been 
reported. Less commonly, allergic reactions have 
been reported. Since 2009, the FDA required 
the possible associations between the use of 
exenatide and altered renal function to be 
highlighted in the prescribing information.
The optimal role of incretin-based therapies 
is still emerging. However, given their unique 
pharmacological properties, it is imperative that 
we explore further their changing roles within 
our treatment algorithms for T2DM. Most 
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therapies as monotherapy or in combination 
with standard OADs.5,22 Accordingly, a growing 
number of treatment guidelines now incorporate 
incretin-based therapies, generally suggesting 
their consideration as add-ons to metformin 
or metformin plus other OAD combination 
therapy, and before resorting to insulin.2
Exenatide has also been compared with 
insulin therapy as an add-on to OAD. Heine 
et al.27 compared response to addition of 
exenatide (10 μg b.i.d.) versus insulin glargine 
(titrated to target fasting plasma glucose [FPG] of 
<5.6 mmol/L) in sub optimally controlled T2DM 
with metformin and/or sulfonylurea. At the 
end of the 26-week period both exenatide and 
insulin glargine reduced hemoglobin A1c (HbA1c) 
levels by 1.11% (difference, 0.017 percentage 
point [95% CI –0.123 to 0.157 percentage 
point]). Exenatide reduced postprandial 
glucose excursions more than insulin glargine, 
while insulin glargine reduced fasting glucose 
concentrations more than the exenatide group. 
In addition, subjects in the exenatide group lost 
an average of 2.3 kg, but also showed a higher 
incidence of gastrointestinal side effects. On 
the other hand, the glargine group had lower 
FPG levels, but with an average weight gain of 
1.8 kg. There were similar rates of hypoglycemia 
in both groups; nocturnal hypoglycemia was 
less common in the exenatide group (0.9 event/
patient-year versus 2.4 events/patient-year; 
difference, –1.6 events/patient-year [CI, –2.3 to 
–0.9 event/patient year]).
Exenatide has also been compared with 
biphasic insulin aspart.28 In a 52-week 
randomized control trial, glycemic control 
achieved with exenatide was non-inferior to 
that achieved with biphasic insulin aspart 
(mean±standard error of mean [SEM], HbA1c 
change: exenatide −1.04± 0.07%, biphasic 
insulin aspart −0.89±0.06%; difference −0.15 
[95% CI −0.32 to 0.01]%). The exenatide group 
showed a weight reduction of 2.5 kg, while the 
biphasic insulin group had a weight increase of 
2.9 kg. Liraglutide has shown favorable effects 
on glycemic control in comparison to insulin 
glargine (significant HbA1c reduction [liraglutide 
vs glargine] 1.33% vs 1.09%; –0.24% difference, 
95% CI 0.08, 0.39; P=0.0015) and placebo 
(–1.09% difference, 95% CI 0.90, 1.28; P<0.0001) 
in the 26-week randomized Liraglutide Effect 
and Action in Diabetes (LEAD)-5 trial.29
GLP-1 receptor agonists
(incretin mimetics)
DPP-4 inhibitors
(incretin enhancers)
Mode of action Increased receptor signaling, results 
in pharmacological levels of GLP-1, 
specific effect and hence results in extra-
pancreatic effects such weight loss and 
delayed gastric emptying
Increased levels of circulating GLP-1; non-
specific, limited by endogenous secretion
Route of delivery Parenteral (subcutaneous injection) Oral
HbA1C reduction 0.8% to 1.8% 0.5% to 1.1%
Effects on weight Induces weight loss Weight neutral
Side effects Increased GI symptoms, potentially 
increased propensity to cause 
hypoglycemia, in comparison
Fewer GI side effects and comparatively reduced 
risk of iatrogenic hypoglycemia
DPP-4=dipeptidyl peptidase-4; GI=gastrointestinal; GLP-1=glucagon-like peptide-1; HbA1C=hemoglobin A1c.
Table 2. Comparing different types of incretin based therapy.150 Diabetes Ther (2011)  2(3):146-161.
There was greater weight loss with liraglutide 
versus placebo (treatment difference –1.39 kg,
95% CI 2.10, 0.69; P=0.0001), and versus glargine 
(treatment difference –3.43 kg, 95% CI 4.00,
2.86; P<0.0001). 
Furthermore, the phase 3 Diabetes Therapy 
Utilization: Researching Changes in A1C, 
Weight and Other Factors Through Intervention 
With Exenatide Once Weekly (DURATION-3) 
trial compared once weekly exenatide against 
glargine.30 In this 26-week, open-label, 
randomized, parallel study, exenatide was 
compared with insulin glargine in adults with 
suboptimally controlled T2DM, despite using 
the maximum tolerated doses of OADs for 
3 months or longer. Investigators randomly 
allocated 456 patients to treatment, who were 
included in the modified intention-to-treat 
analysis (233 exenatide, 223 insulin glargine). 
The change in HbA1c at 26 weeks was greater 
in patients taking exenatide (n=228; −1.5%, 
standard error [SE] 0.05) than in those taking 
insulin glargine (n=220; −1.3%, 0.06; treatment 
difference −0.16%, 0.07, 95% CI −0.29 to −0.03). 
A planned extension period (up to 2.5 years’ 
duration) is in progress.30
Given the evidence, incretin-based therapy in 
T2DM now appears to be well established as the 
second- or third-line agents prior to initiation 
of insulin.2,31 However, there are arguments for 
the adoption of incretin-based therapies earlier 
in the natural history of T2DM. Since GLP-1 
acts as an insulin secretagog, incretin-based 
therapies are likely to have their optimal effect, 
while beta-cell function is preserved. There is 
also evidence from in vitro and animal studies 
that these agents could preserve beta-cell mass 
and function, and hence, potentially slow or 
halt disease progression.16,17 Moreover, there 
is increasing interest in using the incretins in 
combination with exogenous insulin therapy. 
The next section reviews the potential clinical 
role of such regimens, given the pathophysiology 
of T2DM. 
Future Role For Incretin Therapy 
Hyperglycemia in T2DM typically manifests 
initially as elevated postprandial glycemia 
(PPG), followed by fasting hyperglycemia.32,33
Furthermore, postprandial insulin secretion 
is greatly influenced by the incretin system, 
and the incretin system appears to be 
impaired in T2DM. Moreover, glucagon 
secretion is inappropriately elevated in T2DM. 
Hence, hepatic glucose output is increased, 
contributing to both postprandial and fasting 
hyperglycemia.34,35 It is, therefore, logical that 
treatment of T2DM should ideally address 
the ensuing PPG excursions as well as fasting 
hyperglycemia. The incretin system is clearly 
adapted (in normal physiology) to participate in 
the regulation of nutrient ingestion and disposal 
in general, and to help limit PPG excursions in 
particular. Thus, incretin-based therapies should 
prove helpful in this respect and more effective 
than traditional OADs, which do not directly 
address or effectively curtail PPG. Moreover, 
traditional insulin secretagogs (notably the SU) 
cannot improve PPG by enhancing alpha-cell 
function.36
PPG can, of course, be addressed by the 
use of short-acting mealtime insulins, but 
these carry a higher risk of hypoglycemia 
than basal insulin,37,38 and their use requires 
frequent injection and glucose monitoring. 
Short-acting insulin also requires patients to eat 
to ‘counter their insulin’, which compromises 
weight management. Consequently, in T2DM, 
basal-only insulin supplementation added 
to metformin (and sometimes other OADs) 
has gained popularity, particularly in primary 
care, as a simple and tolerable approach to 
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vindicated by the Treating to Target in Type 2 
Diabetes (4T) study in which the choice of a 
basal-only insulin initiation regimen (using 
insulin detemir) resulted in a lower cumulative 
burden of hypoglycemia and weight gain, 
but similar HbA1c achievement after 3 years 
when compared to insulin initiation with 
either prandial or premixed insulin products.38 
Although basal insulin supplementation does 
not directly address PPG, it carries a low risk of 
hypoglycemia and may help to rest the beta-cell 
and relieve glucotoxicity, thereby potentially 
allowing partial recovery of the endogenous 
prandial insulin response.39-41 However, with 
further disease progression, basal insulin alone 
often proves insufficient to maintain control 
of HbA1c, obliging the addition of prandial 
insulins. The 4T study illustrated this point 
by showing that a high percentage of patients 
commencing treatment with basal insulin 
required intensification of their initial regimen 
(67.7 % in the biphasic group, 73.6 % in the 
prandial group, and 81.6 % in the basal group; 
P=0.002 for the overall comparison) within the 
3-year study period.38
An alternative to adding bolus insulins 
to basal insulin might be to combine basal 
insulin with an incretin since the latter glucose-
dependently maximize the preserved prandial 
insulin response while reducing glucagon levels 
in the setting of hyperglycemia. This would be 
particularly applicable to either a short acting 
GLP-1 receptor agonist (eg, exenatide) or a DPP-4 
inhibitor. Studies comparing such combinations 
of incretin-based therapy have been mentioned 
further on (Table 3A and 3B). Placebo-controlled 
clamp studies have shown that both GLP-1 
receptor agonists (exenatide11) and DPP-4 
inhibitors (vildagliptin10) reduce glucagon 
secretion in conditions of hyperglycemia or 
euglycemia, yet increase glucagon output during 
hypoglycemia. Irrespective of the mechanism, 
the observation of an enhanced counter-
regulatory response is consistent with clinical 
reports of low hypoglycemia rates with these 
drugs,5,22 and opens up the fascinating prospect 
of an incretin plus insulin regimen providing 
superior glucose control with a lower risk of 
hypoglycemia than an insulin regimen without 
incretin. 
Another argument supporting this concept 
is that incretin-based therapies (particularly 
GLP-1RA) added to plus basal insulin could 
negate the weight gain associated with 
insulin that can arise through a number 
of potential mechanisms - including the 
retention of previously excreted glucose and 
an inappropriately high exposure of adipocytes 
to insulin after systemically administered.42
This offers the prospect of improved glycemia 
without weight gain. Finally, it is important 
to note that current practice is to maintain 
metformin in insulin-treated T2DM, and this 
approach is compatible with additional incretin 
therapy. As well as directly inhibiting hepatic 
glucose and increasing tissue sensitivity to 
insulin,43 metformin also increases GLP-1 
levels.44 This increase follows metformin-
mediated increased GLP-1 production45 and 
DPP-4 inhibition.46,47 Thus, metformin is 
likely to act additively or synergistically with 
both DPP-4 inhibitors and GLP-1 derivatives. 
Indeed, DPP-4 inhibitors have been found to 
be significantly more effective when combined 
with metformin than when introduced 
as monotherapy in previously drug-naive 
patients.48,49 Hence, fixed-combination 
products are now available. In short, a regimen 
of incretin-based therapy plus basal insulin 
could mimic the pharmacological benefits of 
basal-bolus insulin therapy, but without the 
attendant calorie counting, and the associated 
risks of hypoglycemia and weight gain 
(Table 4). 152 Diabetes Ther (2011)  2(3):146-161.
Study Design Patients (n) Duration Results
GLP-1 based
Yoon et al. 
200950
Retrospective analysis, 
heterogeneous group; mean 
baseline HbA1C 8.05%.
Exenatide added to insulin 
(different regimes).
188 27 months 
(split 
in four 
intervals)
Sustained HbA1C reduction
Initial weight loss, maximum mean 
loss of 6.2 kg (P<0.001) from baseline 
in 12-18 month interval. Adverse 
effects - mainly GI (mild). Two 
serious adverse events: 1) acute renal 
failure (one patient, not related to 
exenatide); 2) acute pancreatitis (one 
patient in one month after starting 
exenatide).
Buse et al. 201051 Prospective placebo controlled, 
randomized study; 12 years 
duration of T2DM.
Addition of exenatide or 
matched placebo or glargine 
(+/- OAD). 
259 30 weeks HbA1C  reduced by 1.7% from baseline 
(8.3%) while in placebo group, HbA1C 
reduced by 1% from baseline (8.5%; 
P<0.001, between treatments). Placebo 
group showed 1 kg weight gain, while 
exenatide group showed weight loss of 
1.8 kg (P=0.001, between treatments).
Significantly more GI side effects 
in the exenatide group with nausea 
experienced by 41% versus 8%.
Arnolds et al. 
201055 
(both GLP-1 and 
DPP-4 inhibitor 
based)
Proof of concept study. 
Prospective, single centre study 
involving both GLP-1 analog 
and DPP-4 inhibitor. Assess 
post-prandial glycemic control 
while comparing the response 
of addition of exenatide (5-10 
μg b.i.d.) or sitagliptin (100 mg 
o.d.) or no further treatment 
to a regime of metformin and 
insulin glargine (titrated to 
fasting blood glucose target 
<5.6 mmol/L)
48 4 weeks The six-hour postprandial blood 
glucose excursion was significantly 
lower with both exenatide 
(P=0.0036) and sitagliptin 
(P=0.0008) compared to the non-
incretin intervention group. HbA1C 
changed by –1.9% (exenatide), 
–1.5% (sitagliptin) and by –1.2% 
in the non-intervention group. 
Hypoglycaemia rates were low. 
Weight loss was seen in the exenatide 
group (–0.9 kg) and was significantly 
different to a slight gain in the non-
incretin group (+0.4 kg, P=0.0377)
DPP-4 inhibitor 
based
Fonseca et al. 
200752
Prospective placebo controlled, 
randomized study, mean 
duration 14.7 years of T2DM, 
mean HbA1C 8.4% on high dose 
insulin with average three
296 24 weeks Mean HbA1C change: –0.5% in the 
vildagliptin group and –0.2% in the 
placebo group (P=0.01 between 
treatments difference). No difference 
in adverse events rate between both
Table 3. Studies comparing combination of insulin with incretin-based therapies.
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Study Design Patients (n) Duration Results
Fonseca et al. 
200752 
(cont.)
injections/day. Randomized to 
receive 50 mg b.i.d. of vildagliptin 
or matched placebo.
groups. Both mild (1.95 vs 2.96 events/
patient/year, P<0.01) and severe 
hypoglycemia (0.0 vs 0.1 events/
patient/year, P<0.05) were less common 
in the vildagliptin group. 
Rosenstock et al. 
200953
Prospective, placebo-controlled, 
randomized study. Mean 
duration of T2DM 12-13 years 
with baseline HbA1C of 9.3%. 
Once daily alogliptin (12.5 mg 
or 25 mg) or placebo added to 
insulin therapy +/- metformin. 
No change in insulin dose.
390 26 weeks HbA1C change: –0.63% with 12.5 and 
–0.71% with 25 mg of alogliptin versus 
–0.13 % with placebo; P<0.001). No 
difference in reported hypoglycemia.
Vilsboll et al. 
200954
Prospective placebo controlled 
randomized study. Duration 
of T2DM >12 years with 
mean baseline HbA1C of 
>8.6%. Sitagliptin 100 mg or 
placebo was added to insulin 
(basal or premixed regimes) 
+/- metformin. Insulin and 
metformin doses were kept 
constant.
641 24 weeks HbA1C changed by –0.6% in the 
sitagliptin group with no change 
in the placebo group (P<0.001) 
Hypoglycemia was more common with 
sitagliptin. No significant change in 
body weight.
Fonseca et al. 
200867
Extension of previous study 
from 2007. Patients in placebo 
group were given vildagliptin 50 
mg/day.
200 52 weeks Patients on 50 mg b.i.d. of vildagliptin 
from the original study showed 
sustained HbA1C reduction (–0.5%). 
Those who switched from placebo to 
vildagliptin 50 mg o.d. showed mean 
reduction of –0.4%. Weight remained 
stable.
Study Design Patients (n) Duration Results
GLP-1 based
Riddle et al. 
201056
Pilot study, mean duration of 
T2DM 8.5 years on metformin 
plus exenatide 10 μg b.i.d. for 
an 8 week run up period. Later 
randomized (blinded) to receive 
glargine with exenatide or 
glargine with placebo instead of 
exenatide.
38 32 weeks 
(including 8 
weeks run-
up period)
HbA1C reduced from 7.8% to 7.3% in 
the placebo group (glargine only) while 
reduced to 6.45% in those continued 
on exenatide (P=0.06 between 
groups). Greater proportion of patients 
continuing exenatide reached HbA1C 
<7% (76% versus 24%, P=0.003) 
Weight increased by 4.1 kg in the 
placebo group (discontinued
B154 Diabetes Ther (2011)  2(3):146-161.
Study Design Patients (n) Duration Results
Riddle et al. 
201056 (cont.)
exenatide) and by 0.4 kg gain in those 
on combination therapy. No severe 
hypoglycaemic events.
Blevins et al. 
201057
Prospective study, addition 
of glargine or insulin lispro 
(protaminated) to exenatide 
(used >3 months) plus OAD. 
Mean duration of T2DM 9.9 
years with mean HbA1C of 8.2%
339 24 weeks HbA1C decreased by 1.16% in 
the lispro group and by 1.40% in 
the glargine group with modest 
weight gain (+0.3 kg and +0.7 kg 
respectively).
Levin et al. 
201068
Retrospective audit, data from 
20 clinical practices. Effect 
of adding glargine, exenatide 
or the combination of two to 
OAD was assessed.
Glargine (93) 
- mean age 65 
years.
Exenatide 
(150) - mean 
age 59 years.
Combination 
(74) - mean 
age 60 years.
– HbA1C reduction varied, as did the 
baseline control. Changes of –1.51% 
(glargine, baseline 9.2%), –0.86% 
(exenatide, baseline 8.2%) and –0.81% 
(combination, baseline 8.5%). The 
glargine only group  gained 1.3 kg) 
while those on exenatide, alone (–3.25 
kg) or in combination (–2.65 kg) lost 
weight.
DPP-4 inhibitor 
based
TRANSITION
study 201169
Prospective study in insulin-naïve 
patients. Compared simultaneous 
addition of sitagliptin plus insulin 
detemir (with discontinuation of 
SU) to introduction of sitagliptin 
alone with SU continued. 
Metformin was continued for 
both groups. Mean HbA1C of 
8.5% on metformin and SU.
217 26 weeks HbA1C changed by –1.44% with 
detemir plus sitagliptin and -0.89% 
with sitagliptin +/- SU (P<0.001%) 
FPG levels were significantly lower in 
the group on detemir with sitagliptin 
(FPG decreased by 3.7 mmol/l)than 
with sitagliptin +/- sulphonylurea (FPG 
decreased by 1.2 mmol/L; P<0.001). 
Self-monitored plasma glucose profiles 
suggested that 2-hour postprandial 
glucose levels were significantly lower 
with detemir plus sitagliptin.
b.i.d.=twice daily; DPP-4= dipeptidyl peptidase-4; FPG=fasting plasma glucose; GI=gastrointestinal; GLP-1= glucagon-
like peptide-1; HbA1C= hemoglobin A1c; OAD= o.d.=once daily; SU=sulfonylureas; T2DM-type 2 diabetes mellitus. 
Clinical Evidence Supporting Adding 
Incretin-Based Therapies to Basal Insulin
Recent clinical studies allude to the advantage 
of adding incretin-based therapies to basal 
insulin, especially in terms of offsetting the 
associated weight gain as well as the reduction 
or neutrality in incidence of hypoglycemia.50-55 
These effects are observed even when incretin-
based therapies are added at a relatively 
later stage of disease. There have also been 
some studies assessing insulin added to 
incretin-based therapies.56,57 Data from these 
studies, albeit limited, demonstrates that a Diabetes Ther (2011)  2(3):146-161. 155
Potentially delay or avert the need for insulin
Low risk of hypoglycemia in comparison to insulin 
therapy
Weight gain associated with insulin initiation might be 
minimized by established incretin therapy
Tolerance to nausea is established before insulin is 
introduced
Table 4. Benefits of introducing incretin therapy before 
establishing patients on insulin.
GLP-1RA can continue to make a major 
contribution to glucose lowering once insulin 
is introduced and supports yet another 
theoretically appealing treatment approach 
(Table 4).
On the other hand, there are 
pathophysiological and pharmacological 
arguments for introducing incretin therapies 
early in the disease process before insulin is 
needed. For example, the insulin-releasing effect 
of incretins is likely to decline with progressive 
beta-cell failure. A recent study in T2DM patients 
showed that the proinsulin: C-peptide ratio of a 
beta-cell response to GLP-1 is reduced following 
a period of near-normoglycemia with insulin 
treatment,58 implying that the insulinotropic 
effect of GLP-1 is more efficient when beta-
cells are less stressed. Any ability to reverse or 
preserve beta-cell mass is also likely to decline 
with disease progression.16 
As incretin and insulin therapy becomes 
more widely used, many more studies will 
be published. At present, however, with the 
exception of the Arnolds et al. pilot study,55 we 
lack any trials that directly compare alternative 
incretin therapies in combination with insulin 
or alternative insulins combined with an 
incretin therapy. Nevertheless, the evidence so 
far suggests that GLP-1RA are more effective at 
mitigating insulin-associated weight gain and 
generally tend to provide somewhat greater 
reductions in hyperglycemia than DPP-4 
inhibitors. Both liraglutide59 and extended 
release exenatide60 have been shown to lower 
HbA1c and reduce weight to a greater extent than 
sitagliptin when added to metformin. 
However, possible tolerability advantages 
for the DPP-4 inhibitors, such as their oral 
administration and a reduced likelihood of 
nausea and, perhaps, hypoglycemia,5 must 
be weighed against these efficacy advantages 
of the GLP-1RA. Such issues and the relative 
performances of incretin plus basal insulin 
regimens versus basal plus bolus insulin 
regimens at various stages in the T2DM disease 
process require testing in future trials. It would 
also be interesting to study the effects of 
combination of DPP-4 inhibitors with GLP-1RA, 
with and without insulin. DPP-4 plays a role in 
the metabolism of at least some of the GLP-1RA, 
such as liraglutide;61 the two drug types could 
potentially be combined synergistically.   
It is also unclear how the efficacy of various 
incretin plus insulin regimens will change 
longitudinally in the course of the T2DM 
disease process, and hence, whether and how 
we will need to adapt dosing. Some data, mostly 
preclinical, had suggested that prolonged 
stimulation of GLP-1 receptors might cause 
desensitization.62 The effects studied on islet 
cells, however, did not translate into clinical 
desensitization in vivo. Recently, there has also 
been some human data published in line with 
GLP-1 receptor desensitization and possible 
tachyphylaxis.63 Nauck and colleagues63
administered native GLP-1 continuously for 
8.5 hours to healthy human subjects without 
T2DM, and assessed the glucoregulatory 
responses to liquid test-meals given 5 hours apart 
with ongoing continuous GLP-1 infusion. The 
ability of GLP-1 to inhibit gastric emptying and 
glucagon levels was significantly reduced by the 
second test meal. However, C-peptide and insulin 
levels were preserved but slightly diminished 156 Diabetes Ther (2011)  2(3):146-161.
with the second meal. Levels of pancreatic 
polypeptide, a marker of vagal activation, were 
not as inhibited during the second test meal. 
Hence, even short-term continuous GLP-1 
receptor stimulation may be association with 
some degree of rapid tachyphylaxis, mostly 
evident in effects mediated through the vagus 
nerve and gastric emptying.63
Immunogenicity is another factor 
which may potentially affect the efficacy of 
intecrin-based therapies, affecting especially 
GLP-1RA. Most of the data around antibodies 
is based on the findings of the LEAD-6 and 
DURATION-1 trials.64,65 LEAD-6 was a 
26-week trial comparing exenatide 10 μg b.i.d. 
against liraglutide 1.8 mg o.d. with a 52 week 
extension period following switch over from 
exenatide to liraglutide therapy.64 DURATION-1 
compared exenatide 10 μg b.i.d. against once 
weekly exenatide long-acting release (LAR) 
(2 mg) over 30 weeks.65 High titers were noted 
for antibodies against exenatide (61% at week 
26), whereas low titers were observed for anti-
liraglutide antibodies (2.6 % at week 79 of 
continued liraglutide therapy, 3% at week 79 in 
group switched from exenatide to liraglutide in 
week 26).64 After the switch from exenatide to 
liraglutide, the percentage of patients with anti-
exenatide antibodies decreased to approximately 
18% by the end of the 78 weeks.64 The presence 
of persistent anti-exenatide antibodies did not 
appear to compromise glycemic response. On 
the contrary, patients with the highest titers of 
anti-exenatide antibodies also had the greatest 
reduction in HbA1C.64 In DURATION-1, anti-
exenatide antibody levels were higher with 
exenatide taken once a week (P=0·0002 vs 
exenatide b.i.d.); however, most antibodies 
were either not detectable or of low (<1/625) 
titre.65 Despite the presence of higher antibody 
titers, a significantly greater reduction in HbA1C 
(1.9%) was observed in the exenatide LAR group 
in comparison to the exenatide b.i.d. group.65 
Therefore, based on the findings of head-to-head 
trials, antibody generation was more pronounced 
for exenatide LAR and less with liraglutide. 
Overall, liraglutide is less immunogenic than 
exenatide and antibody titers do not appear to 
affect glycemic efficacy or safety.64
Another related question is whether there 
is a continuing role for incretin therapies 
when prandial insulin becomes necessary. An 
ongoing effect on alpha-cell function would 
imply that there could be a useful role for 
incretin therapies in late-stage T2DM and even 
type 1 diabetes.66 The prospect of prolonged 
use of incretin therapies also requires us to 
study the long-term safety profiles of these 
agents and regimens. Many useful new insights 
are likely to emerge from epidemiological 
and observational studies, as well as those 
expected from the randomized trials currently 
in progress. In addition, and most importantly, 
data in terms of hard cardiovascular endpoints 
with prolonged use of incretin-based therapy, 
have yet to accumulate. 
Where and When Should We Use Incretin-
Based Therapy Plus Insulin? 
Treatment guidelines currently position incretin-
based therapies and insulin after conventional 
OAD, but from what we know of T2DM 
pathophysiology and the pharmacology of 
the incretin therapies, current practices may 
not produce optimal results. We believe that 
evidence so far supports the combined use of 
incretins and insulin early in the T2DM disease 
process, albeit in selected patients. However, 
the biggest challenge would be selecting the 
right group of patients who would derive the 
maximum benefit from such a combination. In 
addition, the timing of implementing incretin-
based therapy with insulin would be a major Diabetes Ther (2011)  2(3):146-161. 157
determinant of treatment efficacy. Given that 
progressive beta-cell decline characterizes 
the natural history of T2DM and given the 
dependence of incretin-based therapies on 
endogenous insulin production, it would be 
prudent to initiate therapy while there is still 
some beta-cell function remaining. However, 
to ascertain this in a clinical setting would 
present a big challenge. Furthermore, there 
is a lack of clinical data correlating efficacy of 
incretin-based therapy with declining beta-
cell function. In addition, there is little robust 
data in terms of long-term safety and effect on 
hard cardiovascular endpoints with incretin-
based therapy. Similarly, there is insufficient 
clinical evidence to substantiate potential role 
of incretin-based therapy in increasing beta-cell 
mass and altering T2DM progression.
In our opinion, incretin plus basal insulin 
therapy has a logical rationale and may 
provide excellent efficacy and tolerability in 
the treatment of T2DM for a very selective 
group of patients. It is, perhaps, better 
to start with an incretin-based agent and 
then add insulin rather than vice versa as 
this avoids the complexity of having to 
down-titrate insulin, and any nausea issues 
with GLP-1RA are likely to have subsided 
with this sequence. While we advocate 
the introduction of incretin-based therapy 
prior to insulin, we also stress that patients 
suboptimally controlled on high-dose basal 
insulin can nevertheless benefit from the 
addition of an incretin. Given the evidence 
from combination studies, a DPP-4 inhibitor 
at mealtime with basal/premixed insulin or 
a short acting GLP-1 receptor agonists (b.i.d. 
or o.d.) with basal/premixed insulin might be 
preferred. Once again, due to lack of evidence 
so far, selecting patients who would benefit 
from such a combination would be dependent 
on the clinician’s expertise. Finally, given 
the paucity of data, it would be difficult to 
predict the role of longer acting GLP-1RA 
such as exenatide LAR, in such combination 
therapy.
CONCLUSION
In summary, data from initial studies looking 
at a combination of insulin and incretin-based 
therapy are promising. Though several questions 
still remain to be answered, there is already 
evidence to advocate this tactic in patients who 
are not contraindicated and who have reached 
the point of requiring intensification from 
metformin ± other OAD or metformin plus 
basal-only insulin. The cost of incretin-based 
therapy, however, remains a major limiting 
factor, especially in the United Kingdom where 
healthcare is still primarily state funded. This is 
particularly pertinent in the current economic 
climate. Therefore, and in the absence of long-
term safety data, it would be prudent to exercise 
caution with the use of an incretin-based 
therapy.  
ACKNOWLEDGMENTS
Dr R Ahluwalia declares that has no conflicts of 
interest. Professor J Vora was a member of the 
panel of the guideline development group for the 
NICE guidance for type 2 diabetes- newer agents 
(partial update) but has no further conflicts of 
interest. Dr Ahluwalia is the guarantor for this 
article, and takes responsibility for the integrity 
of the work as a whole.
Open Access. This article is distributed 
under the terms of the Creative Commons 
Attribution Noncommercial License which 
permits any noncommercial use, distribution, 
and reproduction in any medium, provided the 
original author(s) and source are credited. 158 Diabetes Ther (2011)  2(3):146-161.
REFERENCES 
1.  DeFronzo RA. Pathogenesis of type 2 diabetes 
mellitus. Med Clin North Am. 2004; 88:787-835. 
2.  Nathan DM, Buse JB, Davidson MB, et al. Medical 
management of hyperglycaemia in type 2 diabetes: 
a consensus algorithm for the initiation and 
adjustment of therapy. A consensus statement 
of the American Diabetes Association and the 
European Association for the Study of Diabetes. 
Diabetologia. 2009;52:17–30. 
3.  Holman R. Metformin as first choice in oral 
diabetes treatment: the UKPDS experience. J Annu 
Diabetol Hotel Dieu. 2007:13-20. 
4.  Hermansen K, Mortensen LS. Bodyweight changes 
associated with antihyperglycaemic agents in type 
2 diabetes mellitus. Drug Saf. 2007;30:1127-1142. 
5.  Drucker DJ, Nauck MA. The incretin system: 
glucagon-like peptide-1 receptor agonists and 
dipeptidyl peptidase-4 inhibitors in type 2 
diabetes. Lancet. 2006;368:1696-1705. 
6.  Nauck M, Stockmann F, Ebert R, Creutzfeldt W. 
Reduced incretin effect in type 2 (non-insulin-
dependent) diabetes. Diabetologia. 1986;29:46-52.
7.  Nauck MA, Heimesaat MM, Orskov C, Holst JJ, 
Ebert R, Creutzfeldt W. Preserved incretin activity 
of glucagon-like peptide 1 [7-36 amide] but not of 
synthetic human gastric inhibitory polypeptide 
in patients with type-2 diabetes mellitus. J Clin 
Invest. 1993;91:301-307. 
8.  Vilsbøll T, Krarup T, Madsbad S, Holst JJ. Defective 
amplification of the late phase insulin response to 
glucose by GIP in obese Type II diabetic patients. 
Diabetologia. 2002;45:1111-1119.
9.  Meier JJ, Nauck MA. Is the diminished incretin 
effect in type 2 diabetes just an epi-phenomenon 
of impaired beta-cell function? Diabetes. 
2010;59:1117-1125.
10.  Ahrén B, Schweizer A, Dejager S, et al. Vildagliptin 
enhances islet responsiveness to both hyper- and 
hypoglycemia in patients with type 2 diabetes. J 
Clin Endocrinol Metab. 2009;94:1236-1243.
11.  Degn KB, Brock B, Juhl CB, et al. Effect of 
intravenous infusion of exenatide (synthetic 
exendin-4) on glucose-dependent insulin secretion 
and counter regulation during hypoglycemia. 
Diabetes. 2004;53:2397-2403.
12.  Wettergren A, Schjoldager B, Mortensen PE, 
Myhre J, Christiansen J, Holst JJ. Truncated GLP-
1 (proglucagon 78-107-amide) inhibits gastric 
and pancreatic functions in man. Dig Dis Sci. 
1993;38:665-673.
13.  Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like 
peptide 1 promotes satiety and suppresses energy 
intake in humans. J Clin Invest. 1998;101:515-520.   
14.  Mudaliar S, Henry RR. Effects of incretin hormones 
on beta cell mass and function, body weight, 
and hepatic and myocardial function. Am J Med. 
2010;123(Suppl. 3):S19-27.
15.  Tews D, Werner U, Eckel J. Enhanced protection 
against cytokine- and fatty acid-induced apoptosis 
in pancreatic beta cells by combined treatment 
with glucagon-like peptide-1 receptor agonists and 
insulin analogues. Horm Metab Res. 2008;40:172-
180. 
16.  Bosi E. Time for testing incretin therapies in 
early type 1 diabetes? J Clin Endocrinol Metab. 
2010;95:2607-2609. 
17.  Drucker DJ. The biology of incretin hormones. Cell 
Metab 2006;3:153-165. 
18.  Nauck MA, Heimesaat MM, Behle K, et al. Effects 
of glucagon-like peptide 1 on counterregulatory 
hormone responses, cognitive functions, and 
insulin secretion during hyperinsulinemic, 
stepped hypoglycaemic clamp experiments in 
healthy volunteers. J Clin Endocrinol Metab. 2002; 
87:1239-1246. 
19.  Chaudhri O, Small C, Bloom S. Gastrointestinal 
hormones regulating appetite. Philos Trans R Soc 
Lond B Biol Sci. 2006;361:1187-1209. 
20.  Barber TM, Begbie H, Levy J. The incretin pathway 
as a new therapeutic target for obesity. Maturitas. 
2010;67:197-202 
21.  Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch 
CL. Dipeptidyl peptidase-4 (DPP-4) inhibitors for 
type 2 diabetes mellitus. Cochrane Database Syst 
Rev. 2008:CD006739.
22.  Bell TJ and Wright EE Jr. Can therapies that target 
the incretin system improve our ability to treat 
type 2 diabetes? J Natl Med Assoc. 2010;102:511-
523.
23.  Neumiller JJ. Clinical pharmacology of incretin 
therapies for type 2 diabetes mellitus: implications 
for treatment. Clin Ther. 2011;33:528-576.Diabetes Ther (2011)  2(3):146-161. 159
24.  Noel RA, Braun DK, Patterson RE, Bloomgren GL. 
Increased risk of acute pancreatitis and biliary 
disease observed in patients with type 2 diabetes: 
a retrospective cohort study. Diabetes Care. 
2009;32:834-838.
25.  Victoza (liraglutide [rDNA] injection) [prescribing 
information]. Princeton, New Jersey: Novo Nordisk 
Inc; 2011. Available at: http://www.novo-pi.com/
victoza.pdf. Last accessed June 7, 2011.
26.  Hegedüs L, Moses AC, Zdravkovic M, Le Thi T, 
Daniels GH. GLP-1 and calcitonin concentration 
in humans: lack of evidence of calcitonin release 
from sequential screening in over 5000 subjects 
with type 2 diabetes or nondiabetic obese subjects 
treated with the human GLP-1 analog, liraglutide. J 
Clin Endocrinol Metab. 2011;96:853-860.
27.  Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel 
MH, Brodows RG. Exenatide versus insulin glargine 
in patients with sub optimally controlled type 
2 diabetes: a randomized trial. Ann Intern Med. 
2005;143:559-569.
28.  Nauck MA, Duran S, Kim D, et al. A comparison 
of twice-daily exenatide and biphasic insulin 
aspart in patients with type 2 diabetes who were 
suboptimally controlled with sulfonylurea and 
metformin: a non-inferiority study. Diabetologia. 
2007;50:259-267.
29.  Russell-Jones D, Vaag A, Schmitz O, et al. 
Liraglutide vs. insulin glargine and placebo in 
combination with metformin and sulfonylurea 
therapy in type 2 diabetes mellitus (LEAD 
-5 met+SU): a randomised controlled trial. 
Diabetologia 2009;52:2046-2055. 
30.  Diamant M, Van Gaal L, Stranks S, et al. Once 
weekly exenatide compared with insulin glargine 
titrated to target in patients with type 2 diabetes 
(DURATION-3): an open-label randomised trial. 
Lancet. 2010;375:2234-2243.
31.  Type 2 diabetes-newer agents for blood glucose 
control in type 2 diabetes (partial update of 
CG66). National Institute for Health and Clinical 
Excellence (NICE). Short clinical guidance 87. May 
2009.
32.  Coates PA, Ollerton RL, Luzio SD, Ismail I, Owens 
DR. A glimpse of the ‘natural history’ of established 
type 2 (non-insulin dependent) diabetes mellitus 
from the spectrum of metabolic and hormonal 
responses to a mixed meal at the time of diagnosis. 
Diabetes Res Clin Pract. 1994;26:177-187.
33.  Owens DR, Luzio SD, Coates PA. Insulin secretion 
and sensitivity in newly diagnosed NIDDM 
Caucasians in the UK. Diabet Med. 1996;13(9 
Suppl. 6):S19-24.
34.  Dunning BE, Foley JE, Ahrén B. Alpha cell function 
in health and disease: influence of glucagon-like 
peptide-1. Diabetologia. 2005;48:1700-1713. 
35.  Ahrén B. Beta- and alpha-cell dysfunction in 
subjects developing impaired glucose tolerance: 
outcome of a 12-year prospective study in 
postmenopausal Caucasian women. Diabetes. 
2009;58:726-731. 
36.  Ahrén B, Foley JE, Ferrannini E, et al. Changes in 
prandial glucagon levels after a 2-year treatment 
with vildagliptin or glimepiride in patients 
with type 2 diabetes inadequately controlled 
with metformin monotherapy. Diabetes Care. 
2010;33:730-732. 
37.  Holman RR, Thorne KI, Farmer AJ, et al. 
Addition of biphasic, prandial, or basal insulin 
to oral therapy in type 2 diabetes. N Engl J Med. 
2007;357:1716-1730. 
38.  Holman RR, Farmer AJ, Davies MJ, et al. Three-
year efficacy of complex insulin regimens in type 2 
diabetes. N Engl J Med. 2009;361:1736-47.
39.  Meneghini L, Liebl A, Abrahamson MJ. Insulin 
detemir: a historical perspective on a modern 
basal insulin analogue. Prim Care Diabetes. 
2010;4(Suppl. 1):S31-42. 
40.  Garvey WT, Olefsky JM, Griffin J, Hamman RF, 
Kolterman OG. The effect of insulin treatment 
on insulin secretion and insulin action in type II 
diabetes mellitus. Diabetes. 1985;34:222-234. 
41.  Li Y, Xu W, Liao Z, et al. Induction of long-term 
glycemic control in newly diagnosed type 2 
diabetic patients is associated with improvement 
of beta-cell function. Diabetes Care. 2004;27:2597-
602.
42.  Russell-Jones D, Khan R. Insulin-associated weight 
gain in diabetes - causes, effects and coping 
strategies. Diabetes Obes Metab. 2007;9:799-812.
43.  Ahrén B. Novel combination treatment of type 
2 diabetes DPP-4 inhibition + metformin. Vasc 
Health Risk Manag. 2008;4:383-394. 
44.  Mannucci E, Tesi F, Bardini G, et al. Effects of 
metformin on glucagon-like peptide-1 levels in 
obese patients with and without Type 2 diabetes. 
Diabetes Nutr Metab. 2004;17:336-342. 160 Diabetes Ther (2011)  2(3):146-161.
45.  Migoya EM, Miller J, Larson P, et al. Sitagliptin, a 
selective DPP-4 inhibitor, and metformin have 
complementary effects to increase active GLP-1 
concentrations. Diabetes. 2007;56(Suppl. 1):A74. 
46.  Green BD, Irwin N, Duffy NA, Gault VA, O’Harte 
FP, Flatt PR. Inhibition of dipeptidyl peptidase-IV 
activity by metformin enhances the antidiabetic 
effects of glucagon-like peptide-1. Eur J Pharmacol. 
2006;547:192-199. 
47.  Cuthbertson J, Patterson S, O’Harte FP, Bell PM. 
Addition of metformin to exogenous glucagon-
like peptide-1 results in increased serum glucagon-
like peptide-1 concentrations and greater glucose 
lowering in type 2 diabetes mellitus. Metabolism. 
2011;60:52-6. Epub 2010 Feb 11.
48.  Goldstein BJ, Feinglos MN, Lunceford JK, Johnson 
J, Williams-Herman DE; Sitagliptin 036 Study 
Group. Effect of initial combination therapy with 
sitagliptin, a dipeptidyl peptidase-4 inhibitor, and 
metformin on glycemic control in patients with 
type 2 diabetes. Diabetes Care. 2007;30:1979-1987.
49.  Jadzinsky M, Pfützner A, Paz-Pacheco E, Xu 
Z, Allen E, Chen R; CV181-039 Investigators. 
Saxagliptin given in combination with metformin 
as initial therapy improves glycemic control in 
patients with type 2 diabetes compared with either 
monotherapy: a randomized controlled trial. 
Diabetes Obes Metab. 2009;11:611-622. 
50.  Yoon NM, Cavaghan MK, Brunelle RL, Roach P. 
Exenatide added to insulin therapy: a retrospective 
review of clinical practice over two years in an 
academic endocrinology outpatient setting. Clin 
Ther. 2009;31:1511-1523.
51.  Buse JB, Bergenstal RM, Glass LC, et al. Use of 
twice-daily exenatide in basal insulin-treated 
patients with type 2 diabetes: a randomized, 
controlled trial. Ann Intern Med. 2011;154:103-
112.
52.  Fonseca V, Schweizer A, Albrecht D, Baron MA, 
Chang I, Dejager S. Addition of vildagliptin to 
insulin improves glycemic control in type 2 
diabetes. Diabetologia. 2007;50:1148-1155. 
53.  Rosenstock J, Rendell MS, Gross JL, Fleck PR, 
Wilson CA, Mekki Q. Alogliptin added to insulin 
therapy in patients with type 2 diabetes reduces 
HbA1C without causing weight gain or increased 
hypoglycemia. Diabetes Obes Metab. 2009;11: 
1145-1152. 
54.  Vilsboll T, Rosenstock J, Yki-Jarvinen H, et al. 
Efficacy and safety of sitagliptin when added to 
insulin therapy in patients with type 2 diabetes. 
Diabetes Obes Metab. 2010;12:167-177.
55.  Arnolds S, Dellweg S, Clair J, et al. Further 
improvement in postprandial glucose control 
with addition of exenatide or sitagliptin to 
combination therapy with insulin glargine and 
metformin: a proof-of-concept study. Diabetes 
Care. 2010;33:1509-1515. 
56.  Riddle M, Ahmann A, Basu A, Aroda V, Ratner 
R. Metformin+exenatide+basal insulin vs. 
metformin+placebo+basal insulin: reaching 
a1c <6.5% without weight-gain or serious 
hypoglycaemia (abstract). Diabetes. 2010;59(Suppl. 
1A):LB18.
57.  Blevins TC, Arakaki RF, Liljenquist DR et al. Once-
daily basal insulin added to oral antihyperglycemic 
medications (OAMs) and exenatide (Ex) improves 
glycaemic control in patients (Pts) with type 2 
diabetes (T2D)(abstract). Diabetes. 2010;59(Suppl. 
1A):LB19.
58.  Asmar M, Højberg PV, Deacon CF, Hare K, Holst 
JJ, Madsbad S. Pancreatic beta-cell responses to 
GLP-1 after near-normalization of blood glucose 
in patients with type 2 diabetes. Regul Pept. 
2010;160:175-180.
59.  Pratley RE, Nauck M, Bailey T, et al. Liraglutide 
versus sitagliptin for patients with type 2 diabetes 
who did not have adequate glycemic control with 
metformin: a 26-week, randomised, parallel-group, 
open-label trial. Lancet. 2010; 375:1447-1456. 
60.  Bergenstal RM, Wysham C, Macconell L, et al. 
Efficacy and safety of exenatide once weekly 
versus sitagliptin or pioglitazone as an adjunct 
to metformin for treatment of type 2 diabetes 
(DURATION-2): a randomised trial. Lancet. 
2010;376:431-439. 
61.  Malm-Erjefält M, Bjornsdottir I, Vanggaard J, et al. 
Metabolism and excretion of the once daily human 
GLP-1 analog liraglutide in healthy male subjects 
and its in vitro degradation by dipeptidyl peptidase 
IV and neutral endopeptidase. Drug Metab Dispos. 
2010;38:1944-1953. 
62.  Baggio LL, Kim JG, Drucker DJ. Chronic exposure 
to GLP-1R agonists promotes homologous GLP-
1 receptor desensitization in vitro but does not 
attenuate GLP-1R-dependent glucose homeostasis 
in vivo. Diabetes. 2004;53(Suppl. 3):S205-214.Diabetes Ther (2011)  2(3):146-161. 161
63.  Nauck MA, Kemmeries G, Holst JJ, Meier JJ. Rapid 
tachyphylaxis of the glucagon-like peptide-1–
induced deceleration of gastric emptying in 
humans. Diabetes. 2011;60:1561-1565. 
64.  Buse JB, Garber A, Rosenstock J, et al. Liraglutide 
treatment is associated with a low frequency and 
magnitude of antibody formation with no apparent 
impact on glycemic response or increased frequency 
of adverse events: results from the Liraglutide 
Effect and Action in Diabetes (LEAD) trials. J Clin 
Endocrinol Metab. 2011;96:1695-1702.
65.  Drucker DJ, Buse JB, Taylor K, et al. Exenatide 
once weekly versus twice daily for the treatment 
of type 2 diabetes: a randomised, open-label, non-
inferiority study. Lancet. 2008;372:1240-1250.
66.  Foley JE, Ligueros-Saylan M, He YL, et al. Effect 
of vildagliptin on glucagon concentration during 
meals in patients with type 1 diabetes. Horm 
Metab Res. 2008;40:727-730. 
67.  Fonseca V, Baron M, Shao Q, Dejager S. Sustained 
efficacy and reduced hypoglycemia during one 
year of treatment with vildagliptin added to 
insulin in patients with type 2 diabetes mellitus. 
Horm Metab Res. 2008;40:427-430.
68.  Levin P, Mersey JH, Zhou S, Bromberger L. Clinical 
outcomes using single vs. combination therapy 
with glargine (GLA) or exenatide (EX)(abstract). 
Diabetes. 2010;59(Suppl. 1):P652.
69.  Hollander P, Raslova K, Skjoth TV, Råstam J, Liutkus 
JF. Efficacy and safety of insulin detemir once daily 
in combination with sitagliptin and metformin: 
the TRANSITION randomised controlled trial. 
Diabetes Obes Metab. 2011;13:268-275.